Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 4/20 | 0.51 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.46 |
| ▸ | UNG | P13051 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2553810 | 0.87 | FOLH1 (0.58) | FOLH1MEP1BUNGCYP2D6CYP2C9 | |
| SCHEMBL16559877 | 0.83 | FOLH1 (0.66) | FOLH1MEP1BCYP4F2CYP4A11CYP2D6 | |
| SCHEMBL14176569 | 0.82 | PPARA (0.65) | PPARAPPARG | |
| SCHEMBL10382220 | 0.82 | PPARA (0.65) | PPARAPPARG | |
| SCHEMBL9789538 | 0.82 | PPARA (0.65) | PPARAPPARG | |
| SCHEMBL19301510 | 0.82 | CYP4F2 (0.65) | FOLH1MEP1BCYP4F2CYP4A11CYP2D6 | |
| SCHEMBL289254 | 0.81 | RARB (0.59) | PPARAPPARG | |
| SCHEMBL1876486 | 0.81 | RARB (0.59) | PPARAPPARG | |
| SCHEMBL15766204 | 0.81 | RARB (0.59) | PPARAPPARG | |
| SCHEMBL11442846 | 0.81 | RARB (0.59) | PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024390-B1 | INSULIN DERIVATIVE | NOVO NORDISK AS (DK) | 2015-08-19 | — | — | EP | claimed |
| US-8796205-B2 | Insulin derivative | NOVO NORDISK A/S (DK) | 2014-08-05 | — | — | US | claimed |
| US-20090105121-A1 | Insulin Derivative | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | claimed |
| EP-2024390-A1 | INSULIN DERIVATIVE | Novo Nordisk A/S (DK) | 2009-02-18 | — | — | EP | claimed |
| WO-2007128815-A1 | INSULIN DERIVATIVE | NOVO NORDISK A/S (DK) | 2007-11-15 | — | — | WO | claimed |
| EP-2024390-B1 | INSULIN DERIVATIVE | NOVO NORDISK AS (DK) | 2015-08-19 | — | — | EP | disclosed |
| US-8796205-B2 | Insulin derivative | NOVO NORDISK A/S (DK) | 2014-08-05 | — | — | US | disclosed |
| US-20090105121-A1 | Insulin Derivative | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| EP-2024390-A1 | INSULIN DERIVATIVE | Novo Nordisk A/S (DK) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007128815-A1 | INSULIN DERIVATIVE | NOVO NORDISK A/S (DK) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105121-A1 | Insulin Derivative | INSR, IAPP, GPR119 | FOLH1 1432/4885MEP1B 1348/4885CYP4F2 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.